Mylan, Other Drugmakers Must Pay $67M In Antitrust Suit
The D.C. federal court has ordered generic-drug maker Mylan Pharmaceuticals and chemical companies Cambrex and Gyma Laboratories to pay a combined $67 million to Blue Cross Blue Shield of Massachusetts and...To view the full article, register now.
Already a subscriber? Click here to view full article